Get started

Biotech

OGEN Long into and past earnings! Starting Today!AMEX:OGEN is going to rip into earnings then pull back right before then pop for 100% or more post earnings. Here are my price targets placed for the next week every few days starting with next Monday. DD: OGEN has *1 drug for Oral Mucosis just finished Phase 2 trial, FULL data will be release on earnings call and ironically at the same time they have $15 Million worth of Warrants that will expire the day before. :) Also OGEN as obtained FDA Fast Track approval for this drug and marketing agreements completed in Europe to put it on the shelves immediately if Phase 2 data is good. *1 drug for lowering cholesterol by 70% currently in Phase 1trial, expect results and Ph2 announcement mid/early summer. *$21 Million cash on hand with burn rate of less than 10 Million per year. *This Monday OGEN bought a COVID19 trial drug company with 4,000,000 shares or roughly $1 Million. Trading in a channel, well established bases in this range over the last year or two, no need for extra funding for at least 1 year.
AMEX:OGENLong
by TheStockMarketSniper
1
VBI vaccines $4 EOY Target Successful completion of the pivotal Phase 3 program for Sci-B-Vac®, on-track for submission of regulatory approval applications in the U.S., Europe, and Canada expected to begin in Q4 2020 Announcement of pan-coronavirus vaccine candidate targeting COVID-19, SARS, and MERS – human clinical study material expected to be available in Q4 2020 Expanded immunologic, tumor, and clinical data from recurrent GBM Phase 2a clinical study of VBI-1901 expected mid-year and Q4 2020 Human proof-of-concept data from Phase 1b/2a study of hepatitis B immunotherapeutic, VBI-2601, expected H2 2020 Net cash proceeds of approximately $54 million added to balance sheet from underwritten public offering in April 2020 11 Million shares bought by insider www.sec.gov
VLong
by jfs2152
2
XBI Potential What is XBi? XBI provides exposure to one of the broadest portfolios among US biotech ETFs. The fund equal-weights its portfolio, which in turn emphasizes small- and micro-caps and greatly reduces single-name risk. Thus, the weighted-average market cap is much smaller than some competitors. Unlike other funds in this segment, XBI is a pure biotech play, with relatively small pharma overlap as we see it. This highly efficient fund, which charges less than competing funds, has a history of beating its index due to revenue from securities lending. It has attracted a large asset base and trades with excellent volume. The fund’s alternative take on the space earns it a place on our Opportunities List. Looking like we could see a pull back here or breakout. Risk and reward is in our favor here. if it rejects, it can go to $95 area, if it breaks out, we can just stoploss for $1.
AMEX:XBI
by WallSt007
2
Ahrvo Daily Movers: Horizon Therapeutics-Bullish on this BiotechAbout Horizon Therapeutics Horizon Therapeutics(ticker: HZNP) is a biopharmaceutical company that focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. It has collaboration agreements with Alliance for Lupus Research, Syneos Health, Inc., and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. HZNP was founded in 2005 and is headquartered in Dublin, Ireland. Ahrvo Stock Rankings Horizon Therapeutics is a top-ten ranked stock on Ahrvo, coming in 6th place (out of over 7,000+ stocks we cover) based on the most recent daily rankings. HZNP has an AhrvoScore (overall score) of 99. Over the last 3 months, Horizon has seen a slight increase in AhrvoScore, up 2 points. Momentum Score, Quality Score, Value Score, and Growth Score are top-notch, clocking in at 94, 80, 99, and 99, respectively. All four sub-scores have increased over the last 3 months. Momentum is up 5 points, Quality up 1 point, Value up 5 points, and Growth up 2 points. Furthermore, Horizon Therapeutics ranks higher than its competitors across all stock scores: Ahrvo Score 99 vs. 35, Momentum Score 94 vs. 62, Value Score 99 vs. 14, Quality Score 80 vs. 18, and Growth Score 99 vs. 42. Ahrvo’s proprietary trading signal also indicates that HZNP is currently a STRONG BUY. Our Take Horizon Therapeutics has performed well relative to the S&P 500 (ticker: SPY) and Nasdaq Biotechnology Index (ticker: IBB). Over the last 6 months, HZNP is up +21%, while the S&P 500 and Biotech Index have returned -8% and +10%, respectively. The company is extremely profitable with net margins of 44%. Last year they earned $573 million on $1.3 billion in revenue. Horizon Therapeutics reports Q1 earnings on Wednesday and is expected to beat analyst expectations. HZNP’s orphan drug portfolio should remain resilient and continue to perform well in the face of economic uncertainty. Orphan drugs are created for extremely rare diseases and drug recipients will need HZNP’s remedies irregardless of what happens with the broader economy. The analyst community is positive on the stock as well. Out of the 12 analysts that cover the company, 10 have HZNP rated as a strong buy (3) or buy (7), with 2 holds. Horizon Therapeutics 12-month median price target is $44.60, representing 25% upside from current levels. -Appo Agbamu, CFA This material is for informational purposes only. Under no circumstances should any information or materials presented be used or construed as an offer to sell, or a solicitation of an offer to buy, any securities, financial instruments, investments, or other services. Any investment made is at your sole discretion. There are many factors that you must consider when making an investment decision, including, but not limited to, product features, risks, whether or not an investment meets your investment objectives, risk tolerance, and other personalized factors. Investing in securities involves risks, and there is always the potential of losing your entire investment.
HLong
by AhrvoStockApp
$TEVA - Weekly Chart 2020Teva's earnings May 7th - www.sec.gov Weekly chart is flashing buy signals with the 50SMA Crossing back under the price. Unknowns: COVID-19 impact on TEVA earnings Decision - Wait until after earnings to get in, still to many unknowns. The reason I like TEVA : Possible Turn-around play, looking for teva to turn net-loss to net-profit in the coming years if they continue to lower debt and start turning profit. Earnings (loss) per share attributable to ordinary shareholders: Basic ($) 2020 - Lower? 2019 - (0.91) even lower? 2018 - (2.35) Lower loss 2017 - (16.26) Huge loss 2016 - 0.07 Smaller profit 2015 - 1.84 Profit Diluted ($) 2019 - (0.91) 2018 - (2.35) 2017 - (16.26) 2016 - 0.07 2015 -1.82 www.sec.gov
NYSE:TEVALong
by AaronX
$SYBX can rise in the next daysContextual immersion trading strategy idea. Synlogic is a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. The demand for shares of the company looks higher than the supply. These and other conditions can cause a rise in the share price in the next days. So I opened a long position from $2,32; stop-loss — $2,15. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:SYBXLong
by KozakHlib
MTNB - Bullish Weekly - Trade the Zones - Play the TicksI actually trade this for 15-20% gains on deep supply zones. Last time I got in was .51 so not bad if you understand where to buy in. I like the swings in this stock and has some volume. Bullish weekly at least to start off next week. Might fail right away with the resistance and the highs. Just need a solid open above .73. Still not banking on that. Just wanted to share a decent penny stock that if you know where to buy in then you can get some decent returns over and over. At least for now. "Reasons Why Long-term Faith on Matinas BioPharma Holdings, Inc. (MTNB) Could Pay Off Investors" investchronicle.com
AMEX:MTNB
by DigitalData
$CDTX can rise in the next daysContextual immersion trading strategy idea. Cidara Therapeutics is a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases The demand for shares of the company looks higher than the supply. Due to the spread of COVID-19, the demand for the company`s services rose. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $2,82; stop-loss — $2,59. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:CDTXLong
by KozakHlib
It's hard to overstate how important the NVAX Phase 3 result isNovavax's Nanoflu isn't your typical new drug-- it's a whole new pharmaceutical technology. So it's hard to overstate how important today's positive Phase 3 clinical trial result is. Positive Phase 3 trial data this morning suggest that Novavax's Virus-Like Particle (VLP)-based flu vaccines will be much more effective than existing egg-based vaccines. When you make a vaccine in an egg, it can mutate in the egg and no longer match the flu strains it's supposed to prevent. The VLP vaccines, by contrast, are genetically identical to the targeted flu strains. This increases the vaccines' effectiveness against the targeted strains. Nanoflu also includes something called "adjuvant Matrix-M," which increases the number of antibodies produced in response to the vaccine by something on the order of 50%. Stronger immune response means greater effectiveness, though it also modestly increased the incidence of adverse events in Novavax's trial. One particular important result from the Phase 3 trial was that Nanoflu was more effective than its competitors against A/H3N2, the most lethal family of flu viruses and the one against which vaccines have traditionally been least effective. I have some friends doing work in this field, and they've told me that there are three really exciting things about these VLP vaccines: 1) they aren't infectious, which makes them safer than using an attenuated virus, 2) they protect against not only the strain of virus they target, but also some mutant forms of it, and 3) they take 12 weeks to produce rather than the traditional 9 months. This last point is the real game-changer. Imagine being able to get vaccines to market in a third of the traditional time. Novavax is also working on a VLP-based Covid-19 vaccine. We can probably expect the FDA to rush approval of both Nanoflu and the CoV-19 vaccine.
NASDAQ:NVAXLong
by ChristopherCarrollSmith
5
$CHMA can rise in the next daysContextual immersion trading strategy idea. Chiasma focuses on developing oral medications using a transient permeability enhancer technology platform for the treatment of rare and serious chronic diseases. The demand for shares of the company looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $4,05; stop-loss — $3,96. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
CLong
by KozakHlib
$IMMU can rise in the next daysContextual immersion trading strategy idea. The demand for shares of Immunomedics looks higher than the supply. It is a clinical-stage biopharmaceutical company, which develops monoclonal antibody-based products for the targeted treatment of cancer. On 06APR the company announced that its Phase 3 confirmatory ASCENT study will be halted due to compelling evidence of efficacy. This drug has the potential to be the first FDA-approved conjugate for the treatment of metastatic triple-negative breast cancer — finance.yahoo.com This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $19,37; stop-loss — $18,60. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
ILong
by KozakHlib
$CBPO can fall in the next daysContextual immersion trading strategy idea. The demand for shares of China Biologic Products Holdings looks lower than the supply. This and other conditions can cause a fall in the share price in the next days. So I opened a short position from $99,86; stop-loss — $102,65. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
CShort
by KozakHlib